Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Hypertension, Cardiovascular Risk, Blood...
Phase Not Applicable
Enrollment 15000
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Because Aktiia S.A. has been the first-ever company to put in the market an Optical Blood Pressure Monitoring device, there is a need for Aktiia S.A. to correlate for the first time continual Blood Pressure monitoring and the evolution of environmental and health factors to improve hypertension management.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Lifestyle survey completion — For the next 10 years, starting at their inclusion in the research project and every 6 months thereafter: fill in an online survey on their lifestyle- health- socioeconomic environment. The completion of a survey lasts 5min maximum.
  • Other: Unlimited on-demand blood pressure measurements with G2C — For the next 10 years: take unlimited on-demand measurements with the Aktiia G2C feature (finger measurement) while seated
  • Other: Continual blood pressure measurements with G1 — For the next 10 years: wear their 24/7 Aktiia G1 device continuously as they would outside the context of the research project.

Primary Outcomes

  • Multivariate models relating data from 24/7 Aktiia the G1 device continual BP monitoring with sociodemographic - lifestyle - and health factors (10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-12
Completion: 2035-05-31
Eligibility
Age: 21 Years – 85 Years
Sex: ALL
Volunteers: true
Enrollment: 15000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aktiia SA
Contact Information
Study Contact:
Pascale Vermare
+41 32 552 20 52
pascale.vermare@aktiia.com
Pr Wuerzner, MD
+41 21 314 02 23
gregoire.wuerzner@chuv.ch
Fully remote study- no physical investigational site
Dr. Manish SAXENA, MD
0207 882 3856
m.saxena@qmul.ac.uk
Fully remote study- no physical investigational site
Interventions
  • Other: Lifestyle survey completion — For the next 10 years, starting at their inclusion in the research project and every 6 months thereafter: fill in an online survey on their lifestyle- health- socioeconomic environment. The completion of a survey lasts 5min maximum.
  • Other: Unlimited on-demand blood pressure measurements with G2C — For the next 10 years: take unlimited on-demand measurements with the Aktiia G2C feature (finger measurement) while seated
  • Other: Continual blood pressure measurements with G1 — For the next 10 years: wear their 24/7 Aktiia G1 device continuously as they would outside the context of the research project.
Study Locations (2 sites)
Fully remote study- no physical investigational site, Lausanne, Switzerland
Fully remote study- no physical investigational site, London, United Kingdom
Eligibility Criteria
Inclusion Criteria: 1. Adult subjects aged 21 to 85 years old 2. Subjects living in Switzerland, Germany or in the UK 3. Subjects that are: Aktiia users owning a smartphone with either iOS or Android operating system (ARMs 1 and 2); or Aktiia non-users owning a smartphone with iOS or Android operating system (ARM 3) 4. Subjects agreeing to follow the study procedures. Exclusion Criteria: 1. Subjects suffering from sustained cardiac arrhythmias that can lead to weak or unstable pressure pulses including resting tachycardia (heart rate at rest \> 120bpm) and atrial fibrillation; 2. Subjects suffering from pathologies that systematically reduce peripheral perfusion including Raynaud's disease, diabetes, renal dysfunctions (eGFR \< 30mL / min / 1.73 m2), untreated hyper-/ hypothyroidism, pheochromocytoma, or arteriovenous fistula; 3. Subjects suffering from polyneuropathy; 4. on pregnant women; 5. Subjects with damaged / injured skin at the wrists (for bracelet measurements) or at index fingers (for camera measurements) 6. Subjects with amputated index fingers (for camera measurements) or amputated upper limb; 7. Subjects below 21 years old and above 85 years old.
Conditions Liver Cirrhosis, Hepatocellular Carcinom...
Phase Not Applicable
Enrollment 150
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Patients with established liver cirrhosis, or end-stage liver disease (ESLD), are at high risk of developing liver cancer (hepatic carcinoma; HCC), portal hypertension, and sarcopenia, all which lead to significant morbidity and mortality. In this patient group the annual incidence of HCC is c. 2-8% and these patients are therefore included in ultrasound HCC screening programs every 6 months. In this study, the investigators are aiming to assess sarcopenia, clinically significant portal hypertension (CSPH), and HCC with a single short magnetic resonance (MR) examination. A neck-to-knee MRI-examination will be acquired to derive body composition profile (BCP) measurements including visceral and abdominal subcutaneous adipose tissue (VAT and ASAT), thigh fat free muscle volume (FFMV) and muscle fat infiltration (MFI), as well as liver fat (PDFF), spleen volume, and liver stiffness. Images will be further processed by AMRA Medical AB. AMRA's solution includes FFMV in the context of virtual control groups (VCG; using AMRA's vast database) and MFI. Furthermore, the spleen volume will be used to monitor the development of portal hypertension and explored together with other BCP variables in relation to hepatic decompensation events. HCC screening will be performed using so-called abbreviated MRI (AMRI), which consists of time series of contrast-enhanced T1-weighted images. The AMRI images will be read by an experienced radiologist. In the literature the sensitivity of AMRI to detect HCC is above 80%, with a specificity of c. 95%, compared to ultrasound sensitivity of 60%. In treating ESLD there is a desire of physicians to be able to predict future decompensation events in order to initiate treatment to prolong survival. Moreover, the ability to assess processes of sarcopenia in the patient would be highly valuable for clinical practice due its severe clinical impact. Finally, ultrasound-based HCC screening has poor diagnostic performance and a MR-based screening approach would significantly improve treatment outcome as more treatable and earlier HCC may be identified.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Body composition (FFMVvcg) (Baseline)
  • Body composition (FFMVvcg) (6 months)
  • Body composition (FFMVvcg) (1 year)
  • Body composition (FFMVvcg) (18 months)
  • Change from baseline Body composition (FFMVvcg) (6 months)
  • Change from 6 months Body composition (FFMVvcg) (1 year)
  • Change from 1 year Body composition (FFMVvcg) (18 months)
  • Muscle fat infiltration (%) [MFI] (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-02-01
Completion: 2030-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Linkoeping University
Collaborators: Amra Medical AB
Principal Investigators:
  • Mattias Ekstedt, MD, PhD (PRINCIPAL_INVESTIGATOR) - Linkoeping University
Contact Information
Study Contact:
Mattias Ekstedt, MD, PhD
+46709296267
mattias.ekstedt@liu.se
Mikael Forsgren, PhD
mikael.forsgren@amramedical.com
Martin Rejler, PhD, MD
martin.rejler@rjl.se
Department of Gastroenterology), District Hospital in Eksjö
Interventions
N/A
Study Locations (3 sites)
Department of Gastroenterology), District Hospital in Eksjö, Eksjö, 57581 Sweden
Department of gastroenterology, County Hospital in Jönköping, Jönköping, 55185 Sweden
Department of gastroenterology and hepatology, Linköping, Sweden
Eligibility Criteria
Inclusion Criteria: 1. Established or probable liver cirrhosis according to clinical practice at the Department of Gastroenterology and Hepatology at Linköping University Hospital. This is not by necessity biopsy verified, it can be different criteria such as FibroScan, symptoms, biopsy, and radiology. 2. Age ≥18 years 3. Written informed consent from the participant Exclusion Criteria: 1. Contraindications for MRI 2. Subjects suffering from primary sclerosing cholangitis (PSC) 3. Subjects diagnosed with Hepatic carcinoma (HCC) 4. Previous liver transplant
Conditions Chronic Thromboembolic Pulmonary Hyperte...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

to detect the incidence of CTEPH patients. Primary outcome To predict CETHP in symptomatic patients after pulmonary embolism episode. Secondary outcome: On Echocardiography revealed RV dysfunction which are peak TR Velocity , the RV/LV basal diameter ratio, flattening of the IVS, RV acceleration time and/or midsystolic notching, IVC diameter with decreased inspiratory collapse and RA area.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Primary Outcomes

  • Incidence of CTEHP in symptomatic patients after pulmonary embolism episode. (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-01
Completion: 2026-12-01
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ester Ashraf Faried Beshay
Principal Investigators:
  • Ester A Faried, Resident (PRINCIPAL_INVESTIGATOR) - Assiut University
Contact Information
Study Contact:
Ester A Faried, resident
01277194352
esterashraf1810@gmail.com
Aly M Tohamy, Professor
01006258877
Ali.Tohamy@gmail.com
Interventions
N/A
Study Locations (1 sites)
Assiut University, Asyut, AssiutU Egypt
Eligibility Criteria
Inclusion Criteria: Any patient diagnosed as acute pulmonary embolism ,aged between 18-80 years old which Pulmonary Embolism Severity Index (PESI) class III-V or sPESI ≥1, Exclusion Criteria: Secondary causes for pulmonary hypertension Severe kidney injury(eGFR\>30 mg/dl/1.7m2) Hepatic affection Contraindication to anti-coagulation
Conditions Hypertension
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Background: Hypertension has long been considered as a major risk factor for cardiovascular disease representing a high public health concern. Objectives: the purpose of this study is to evaluate the effects of combined HIIT and resistance training on body composition, blood pressure, and cardiorespiratory fitness in obese hypertensive men. Methods: This study will make use of sixty obese hypertensive men aged 40 to 60 years. All participants meeting the eligibility criteria will be assigned to one of three groups; combined HIIT and resistance group, HIIT only group or control group. Combined exercise group subjects will undergo weekly three sessions of both HIIT and resistance training for sixteen weeks. The HIIT session will involve four four-minute high-intensity intervals with an intensity of at 80-95% of the HRmax interspersed with two-minute active recovery intervals with intensity of 40% to 60% of the HRmax. The resistance training session will be composed of eight exercises perform 3 sets of 8-12 repetitions with an intensity of 80% of the subject's estimated 1-RM. The HIIT only group perform 12 weeks of HIIT only. The control group subjects will be instructed not to change their usual daily physical activities routine and instructed to abstain from practicing any exercise regimens during the 12-week study period. Body composition measures, blood pressure and VO2peak will be assessed at baseline and at the end of the study period. Results: All the outcome variables will be assessed at baseline and 12 weeks following the treatment period.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Exercise — Combined exercise group subjects will undergo weekly three sessions of both HIIT and resistance training for sixteen weeks. The HIIT session will involve four four-minute high-intensity intervals with an intensity of at 80-95% of the HRmax interspersed with two-minute active recovery intervals with intensity of 40% to 60% of the HRmax.
  • Other: routine physical activity — The control group subjects will be instructed not to change their usual daily physical activities routine and instructed to abstain from practicing any exercise regimens during the 12-week study period.

Primary Outcomes

  • blood pressure in mmhg (12 weeks)
  • peak oxygen consumption in ml/kg/min (12 weeks)
  • body weight in Kg (12 weeks)
  • body mass index in kg/m2 (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-01
Completion: 2025-07-01
Eligibility
Age: 40 Years – 60 Years
Sex: MALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Prince Sattam Bin Abdulaziz University
Contact Information
Study Contact:
Ahmed S Ahmed, PhD
000966564347031
a.aseil@psau.edu.sa
Ahmed Sayed Ahmed
+966564347031
a.aseil@psau.edu.sa
Prince Sattam bin Abdulaziz University
Interventions
  • Behavioral: Exercise — Combined exercise group subjects will undergo weekly three sessions of both HIIT and resistance training for sixteen weeks. The HIIT session will involve four four-minute high-intensity intervals with an intensity of at 80-95% of the HRmax interspersed with two-minute active recovery intervals with intensity of 40% to 60% of the HRmax.
  • Other: routine physical activity — The control group subjects will be instructed not to change their usual daily physical activities routine and instructed to abstain from practicing any exercise regimens during the 12-week study period.
Study Locations (1 sites)
Prince Sattam bin Abdulaziz University, Riyadh, Alkharj 16278 Saudi Arabia
Eligibility Criteria
Inclusion Criteria: * men aged between 40 and 60 years old, * have been diagnosed with clinical stage 1 or 2 hypertension, * being obese with body mass index more than 30 kg/m2 * physically inactive Exclusion Criteria: * musculoskeletal problems that may limit their ability to participate in resistance or HIIT programs * diabetes mellitus * a history of respiratory or chronic heart disease
Conditions Posterior Reversible Encephalopathy Synd...
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Posterior Reversible Encephalopathy Syndrome prospective (PRES) registry. Data collection using a standardized form : demographic data and data related to the PRES, including circumstances of onset, dates and times of onset and of symptoms control, on-scene clinical findings, clinical and radiological features of PRES, pre-hospital and hospital care providers, timing of antiepileptic, antihypertensive drugs and supportive treatments, results of etiological investigations, cause of PRES, type and dosage of antiepileptic and antihypertensive drugs. Dates and times of EEG monitoring, EEG results, radiological and biological investigations. Outcomes including vital status and Glasgow Outcome Scale score at ICU and hospital discharge, day-90 and 1-year after SE and determined based on data in the ICU and/or neurologist charts and/or patients phone interview

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention — No intervention planed

Primary Outcomes

  • Favorable outcome (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2018-03-09
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ictal Group
Collaborators: Versailles Hospital
Principal Investigators:
  • Stephane LEGRIEL, MD (PRINCIPAL_INVESTIGATOR) - Ictal Group
Contact Information
Study Contact:
Stephane LEGRIEL, MD
+33139639717
slegriel@ch-versailles.fr
Stephane LEGRIEL, MD
+33139639717
slegriel@ch-versailles.fr
Intensive Care Unit - Versailles Hospital
Interventions
  • Other: No intervention — No intervention planed
Study Locations (1 sites)
Intensive Care Unit - Versailles Hospital, Le Chesnay, 78150 France
Eligibility Criteria
Inclusion Criteria: * age \>= 18 years * Posterior Reversible Encephalopathy Syndrome defined as: * combination of consciousness impairment, seizure activity, headaches, visual abnormalities, nausea/vomiting, and focal neurological signs AND * cerebral imaging abnormalities involving the white matter (brain CT scan hypodensities AND/OR Brain MRI hypoT1, hyper T2 FLAIR) * intensive care unit admission Exclusion Criteria: * normal cerebral imaging
Conditions Healthy Adult Participants
Phase PHASE1
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This is a single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging from 10 μg to 20 μg.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: L608 Liposomal inhalation suspension — Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.
  • Drug: Placebo Solution — Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.

Primary Outcomes

  • Percentage of participants with DLT (7 days after administration)
  • Percentage of participants with TEAEs and SAEs (2 weeks after administration)
  • Frequency and severity of TEAEs and SAEs (2 weeks after administration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-04-11
Completion: 2026-12-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pharmosa Biopharm Inc.
Collaborators: Novotech (Australia) Pty Limited
Contact Information
Study Contact:
Pei Kan, PhD
+886-2-2782-7561
peikan@pharmosa.com.tw
Sydney Chuang
+886-2-2782-7561
sydney@pharmosa.com.tw
Christopher John Wynne
+64 3 372-9477
chris.wynne@nzcr.co.nz
NZCR Ltd (New Zealand Clinical Research)
Interventions
  • Drug: L608 Liposomal inhalation suspension — Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.
  • Drug: Placebo Solution — Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.
Study Locations (1 sites)
NZCR Ltd (New Zealand Clinical Research), Christchurch, 8011 New Zealand
Eligibility Criteria
Key Inclusion Criteria: 1. Men and women aged between 18 and 65 (inclusive) at the time of Screening visit. 2. Participants with Body Mass Index (BMI) of ≥18.5 and ≤32.0 kg/m2 and weight of at least 50 kg at Screening. 3. Non-smokers or former smokers who have smoked ≤ 100 cigarettes in their lifetime and have not consumed any tobacco or tobacco-containing products for at least 3 months prior to Screening. 4. Females must not be pregnant or lactating and must use acceptable, highly effective double contraception from Screening until 3 months after the last dose of the Investigational product. Key Exclusion Criteria: 1. Participants with contraindications or sensitivity to any components of the study treatment. 2. Participants with histories or active conditions of unexplained bleeding events, hemoptysis, abnormal bleeding tendencies, and/or coagulation disorders. 3. Participants with histories or active conditions of asthma, sleep apnea, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, bronchiectasis, bronchospasm, and/or reactive airway. Subjects who have had childhood asthma which have resolved as deemed by the PI can be considered. 4. Participants with histories or active conditions of myocardial infarction (MI), cerebrovascular accident (CVA), coronary artery disease (CAD), unstable angina, heart failure, significant cardiac arrhythmias, congenital or acquired valvular heart disease with clinically insignificant symptom, suspected lung congestion, and/or pulmonary arterial hypertension (PAH) causing by venous thromboembolism. 5. Cohorts A1 and B1: Participants with systolic blood pressure \< 90 mmHg or \> 140 mmHg and/or diastolic blood pressure \< 50 mmHg or \> 95 mmHg at Screening or check-in visit. Cohorts B2, B3, C1 and C2: Participants with systolic blood pressure \< 110 mmHg or \> 140 mmHg and/or diastolic blood pressure \< 50 mmHg or \> 95 mmHg at Screening, check-in visit or predose on Day1. 6. Participants with FEV1 less than 80% predicted, FVC ˂ 80% predicted, or resting oxygen saturation less than 95% at Screening or check-in visit. 7. Participants with histories of drug or alcohol abuse within 1 year prior to subject check-in (Day -1). Regular alcohol consumption defined as \> 14 standard drinks per week for female and \> 21 standard drinks per week for male. 8. Consumption of products containing caffeine/methylxanthines, poppy seeds and/or alcohol within 48 hours before dosing and products containing grapefruit and/or pomelo (shown to inhibit cytochrome P450 \[CYP\] 3A4 activity) within 10 days prior to drug administration, and/or participants unwilling to refrain from consumption of alcohol from 48 hours before dosing to Day 14. 9. Receipt of blood products within 2 months prior to dosing. 10. Positive results of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and pregnancy test. 11. Blood donation or significant blood loss (\>480 ml) within 3 months prior to Screening. 12. Participants unwilling to refrain from strenuous exercises from 7 days prior to dosing until the EOS visit. 13. Participants planning to receive a tattoo, body piercing, or undergo any invasive procedure during the study period.
Conditions Primary Aldosteronism, Hypertension
Phase PHASE4
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This research study aims to learn more about the impact the hormone aldosterone on the heart. Primary aldosteronism is a condition where the body's adrenal glands make too much of the hormone aldosterone, which can cause high blood pressure and increase the risk of heart and kidney disease. Treatment with medications that block aldosterone can reduce that risk. This study is trying to learn whether treatment with a medication that blocks aldosterone can improve heart function in people who make too much aldosterone.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Eplerenone — After baseline cardiac imaging with PET and echocardiogram, participants will be treated with eplerenone for 6 months at a starting dose of 50mg daily and up to a maximally tolerated dose of 100mg daily, followed by repeat imaging with PET and echocardiogram.

Primary Outcomes

  • Change in myocardial flow reserve (MFR, unitless ratio) (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-12-15
Completion: 2028-02-28
Eligibility
Age: 18 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Brigham and Women's Hospital
Contact Information
Study Contact:
Jenifer M Brown, MD
8573071990
jbrown35@bwh.harvard.edu
Eva Abel
617-525-3803
Brigham and Women's Hospital
Interventions
  • Drug: Eplerenone — After baseline cardiac imaging with PET and echocardiogram, participants will be treated with eplerenone for 6 months at a starting dose of 50mg daily and up to a maximally tolerated dose of 100mg daily, followed by repeat imaging with PET and echocardiogram.
Study Locations (1 sites)
Brigham and Women's Hospital, Boston, Massachusetts 02115 United States
Eligibility Criteria
Cohort A: Overt \& Diagnosed PA Inclusion Criteria: * Adults aged 18-85 * Able to provide informed consent and willing to comply with the study * Able to fit safely in PET/CT scanner (weight limit 500 pounds; diameter and circumference of PET/CT scanner are 70 cm and 220 cm, respectively) * Hypertension treated with at least one antihypertensive drug * Cohort A: Clinically confirmed diagnosis of PA not yet treated with mineralocorticoid receptor antagonists Exclusion Criteria: * History of MI, CABG, known cardiomyopathy (EF \<40%, hypertrophic cardiomyopathy, and/or amyloid), cardiac transplantation * Contraindication or allergy to eplerenone or spironolactone * Current pregnancy or breastfeeding * eGFR \< 45 mL/min/1.73m2 or potassium \> 5.1 on labs within the preceding 3 months * Cohort A: Planned adrenalectomy in the subsequent 6 months Cohort B: Subclinical \& Undiagnosed PA Inclusion Criteria: * Adults aged 18-85 * Able to provide informed consent and willing to comply with the study * Able to fit safely in PET/CT scanner (weight limit 500 pounds; diameter and circumference of PET/CT scanner are 70 cm and 220 cm, respectively) * Hypertension treated with at least one antihypertensive drug * Cohort B: Clinically indicated cardiac PET perfusion scan within the preceding 3 months and echocardiogram within the preceding 6 months Exclusion Criteria: * History of MI, CABG, known cardiomyopathy (EF \<40%, hypertrophic cardiomyopathy, and/or amyloid), cardiac transplantation * Contraindication or allergy to eplerenone or spironolactone * Current pregnancy or breastfeeding * eGFR \< 45 mL/min/1.73m2 or potassium \> 5.1 on labs within the preceding 3 months * Cohort B: 10% or greater burden of ischemia on qualifying PET * Cohort B: Planned coronary angiogram/revascularization in the subsequent 6 months.
Conditions Hypertension, Diabetes
Phase Not Applicable
Enrollment 10000
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Background: * Type 2 diabetes (T2D) and associated complications are major contributors to the global disease burden. T2D is already a major health threat in populations in developed countries and is rapidly taking hold in the developing world. * It is believed that understanding the complex interplay between genetic and lifestyle characteristics in the etiology of T2D and related complications will lead to the development of better preventive and therapeutic strategies. In Addition, the results of this project will facilitate our understanding of causes of diabetes in African Americans, other US and world populations Objectives: * To conduct a genome-wide association study (GWAS) to identify susceptibility genetic variants for diabetes among the Yoruba people in Ibadan, Nigeria. * To enroll and examine 300 unrelated cases of T2D and 300 ethnicity-matched Yoruba controls. * To conduct resequencing of positional candidate gene/loci to identify likely functional variants in a subset of the cohort. * To conduct replication studies of the top-100 scoring variants in three independent African and European ancestry samples. * To investigate whether diabetes-associated variants discovered in European populations increase diabetes risk in West Africans. Eligibility: * Patients 18 years of age with confirmed T2D who are newly diagnosed or on treatment of Yoruba ethnicity in Ibadan, Nigeria. Control subjects are nondiabetics ethnically matched to patients. Design: * The study design for both patients and controls consists of the following steps: * Discuss informed consent process and obtain signed informed consent form. Informed consent will be administered by trained clinic staff. * Assign study ID (barcode) * Administer questionnaires * Obtain spot urine sample * Measure blood pressure * Obtain anthropometric measurements including body composition * Perform finger prick for blood glucose level * Obtain venous blood samples * Perform eye examination * On the following day, perform confirmatory blood glucose for the small subset of participants requiring confirmation of previous test result DNA extraction of stored samples will be done at either the National Institutes of Health or the laboratory in Nigeria. * GWAS will be conducted using publicly available software packages.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • I (ongoing)
  • H (ongoing)
  • G (ongoing)
  • F (ongoing)
  • E (ongoing)
  • D (ongoing)
  • C (ongoing)
  • B (ongoing)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2009-02-03
Completion: Ongoing
Eligibility
Age: 18 Years – 120 Years
Sex: ALL
Volunteers: true
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Human Genome Research Institute (NHGRI)
Principal Investigators:
  • Charles N Rotimi, M.D. (PRINCIPAL_INVESTIGATOR) - National Human Genome Research Institute (NHGRI)
Contact Information
Study Contact:
Shirley T Freeman
(301) 451-2302
freemansh@mail.nih.gov
Charles N Rotimi, M.D.
(301) 451-2303
rotimic@mail.nih.gov
Clement Adebamowo, M.D.
(410) 706-6116
cadebamo@yahoo.com
University of Ibadan
Interventions
N/A
Study Locations (5 sites)
University of Ghana, Accra, Ghana
University of Science and Tech, Kumasi, Ghana
University of Nigeria, Enugu, Nigeria
University of Ibadan, Ibadan, Nigeria
University of Lagos, Lagos, Nigeria
Eligibility Criteria
* INCLUSION CRITERIA: As our primary interest is in T2D, it is important to exclude individuals who may have diabetes of another etiology. Elevated blood glucose in individuals 25 years old or younger is unlikely (in West Africa) to result from T2D and may reflect Type 1 Diabetes. Therefore, only individuals older than 25 years will be included in this study. We are seeking to enroll persons without T2D or with previously or newly diagnosed T2D. Previously diagnosed cases will be determined by self-report of being treated with oral medication or insulin. Newly diagnosed cases will be determined by fasting blood glucose value \>= 126 mg/dl on more than one occasion. Individuals who have elevated blood glucose during their initial reading will be asked to return to the study site for a second test. If this test also has a fasting blood glucose value \>= 126 mg/dl, then they will be considered a new case. The control group will be individuals with no report of T2D diagnosis and fasting plasma glucose (FPG)\< 126 mg/dl. Only unrelated individuals will be included in this phase of the study to avoid confounding genetic association studies by relatedness in the study population. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * Incarceration. * Lack capacity to consent to research participation. * Pregnancy.
Conditions GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized controlled clinical trial is to learn whether two minimally invasive bleb-forming glaucoma implants can effectively treat adult patients with open-angle glaucoma who require surgical lowering of intraocular pressure (IOP). Specifically, the study evaluates whether the PRESERFLO™ MicroShunt is at least as effective as the trabeculectomy in reducing IOP after surgery. The main questions it aims to answer are: Does the PRESERFLO™ MicroShunt provide IOP reduction at 12 months that is non-inferior to trabeculectomy? How do these two surgeries compare over 12 months with respect to medication reduction, need for additional glaucoma procedures, complications, and preservation of visual function and ocular structures? Participants will: Be randomly assigned (1:1) to receive either the trabeculectomy or the PRESERFLO™ MicroShunt during a single glaucoma surgery. Attend scheduled follow-up visits over 12 months for eye-pressure measurements, vision testing, visual-field testing, OCT imaging, endothelial-cell counts, and safety assessments. Receive standard postoperative care and report any complications or additional treatments during the study period.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Preserflo MicroShunt Implantation — The PRESERFLO™ MicroShunt is a SIBS-polymer microshunt. This devices bypasses the trabecular meshwork and lower eye pressure via a subconjunctival filtering bleb, aided by intra-operative mitomycin C to reduce scarring. It has already been approved for the European market and therefore bear the CE mark.
  • Procedure: Trabeculectomy with MMC — Trabeculectomy (TE) has been steadily improved over the last decades and remains globally accepted as the therapeutic gold standard, great efforts are being made to develop alternative surgical options. This is mainly due to the high rate of complications after TE, including hypotony with choroidal detachment, a flat anterior chamber, or hyphema, as well as a complex postoperative follow-up

Primary Outcomes

  • Intraocular pressure (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-01
Completion: 2028-12-01
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Bialystok
Contact Information
Study Contact:
Joanna Konopinska
+48857468372
joanna.konopinska@umb.edu.pl
Joanna Konopinska
+48857468372
joannakonopinska@o2.pl
Medical University of Bialystok
Interventions
  • Device: Preserflo MicroShunt Implantation — The PRESERFLO™ MicroShunt is a SIBS-polymer microshunt. This devices bypasses the trabecular meshwork and lower eye pressure via a subconjunctival filtering bleb, aided by intra-operative mitomycin C to reduce scarring. It has already been approved for the European market and therefore bear the CE mark.
  • Procedure: Trabeculectomy with MMC — Trabeculectomy (TE) has been steadily improved over the last decades and remains globally accepted as the therapeutic gold standard, great efforts are being made to develop alternative surgical options. This is mainly due to the high rate of complications after TE, including hypotony with choroidal detachment, a flat anterior chamber, or hyphema, as well as a complex postoperative follow-up
Study Locations (1 sites)
Medical University of Bialystok, Bialystok, Polska 15-089 Poland
Eligibility Criteria
Inclusion Criteria: -\>21 years of age * An established diagnosis of: Primary open angle glaucoma, Normal tension glaucoma, Pigment dispersion glaucoma (PDG) or Pseudoexfoliative glaucoma (PEXG) * Inadequately controlled on maximum tolerated medical therapy * Mean Deviation (MD) \</= -3 * Intraocular pressure of 14-28 mmHg * Endothelial Cell Count ≥1000 cells/mm2 Exclusion Criteria: * An established diagnosis of: Closed-angle glaucoma or Secondary open-angle glaucoma (besides PDG and PEX) * Lens status: Aphakic patients or Anterior chamber intraocular lens * Previous procedures: Glaucoma shunt/valve/ surgery or cyclodestructive procedure, Selective laser trabeculoplasty within the past 3 months, Incisional ophthalmic surgery involving the conjunctiva within the past 3 months, Clear corneal cataract or trabecular meshwork surgery conducted within the past 6 months * Presence of intraocular silicone oil * No light perception vision * Current corticosteroid use (ocular or oral) * Conjunctival pathologies (e.g., pterygium) * Active inflammation (e.g., blepharitis, conjunctivitis, keratitis, uveitis) * Vitreous present in the anterior chamber * Active iris neovascularization or neovascularization of the iris within 6 months of the surgical date * Unwillingness or inability to give consent, accept randomization or return for and participate in scheduled protocol visits
Conditions Preeclampsia, Gestational Hypertension, ...
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Serum sFlt-1 concentration (At enrollment (20-36 weeks of gestation))
  • Serum PlGF concentration (At enrollment (20-36 weeks of gestation))
  • sFlt-1/PlGF ratio (At enrollment (20-36 weeks of gestation))
  • Serum Osteoprotegerin (OPG) concentration (At enrollment (20-36 weeks of gestation))
  • Serum sENG(Souble Endoglin) concentration (At enrollment (20-36 weeks of gestation))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-10
Completion: 2026-04-30
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ammar Jassim Abed
Contact Information
Study Contact:
Ammar Jassim Abed, MSc
+9647809561105
ammar.jassim11@gmail.com
Ammar Jassim Abed
9647809561105
ammar.jassim11@gmail.com
Bint Al Huda Maternity Hospital
Interventions
N/A
Study Locations (1 sites)
Bint Al Huda Maternity Hospital, Nasiriyah, Dhi Qar 64001 Iraq
Eligibility Criteria
IInclusion Criteria: * Pregnant women between 20 and 36 weeks of gestation * Age between 18 and 45 years * Attending the antenatal clinic at the study site Exclusion Criteria: * Chronic hypertension * Renal disease * Diabetes mellitus * Multiple gestations * Autoimmune disorders
Conditions Hypertension
Phase NA
Enrollment 1200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this cluster randomized controlled trial is to evaluate the effectiveness of a pharmacist-led multifaceted intensive blood pressure intervention on poorly controlled hypertensive patients in phase 1 (1 month, 3 months, 6 months, 12 months) and phase 2 (24 months) post randomization.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Behavioral: pharmacist-led multifaceted intervention — Based on the blood pressure management model of pharmacist-led multifaceted intervention, clinical pharmacists who have received unified training provide pharmaceutical intervention and lifestyle guidance to subjects in the intervention group according to standard protocol. Pharmaceutical interventions include health education, medication adherence (medication consultation, medication reminder), medication reorganization, and rational use of medication. At the same time, clinical pharmacists supervise the subjects to change their lifestyle (including reasonable diet, quitting smoking and drinking, moderate exercise, weight control and ensuring sleep, etc.), and guide the subjects to conduct home blood pressure monitoring.
  • Behavioral: conventional health education — The subjects receive conventional hypertension health education, standard blood pressure measurement training and regular follow-up in the control group.

Primary Outcomes

  • Blood pressure control rate (baseline, 1 month, 3 months, 6 months, 12 months and 24 months after baseline)
  • Time in target range (TTR) (baseline, 1 month, 3 months, 6 months, 12 months and 24 months after baseline)
  • Medication Adherence (baseline, 1 month, 3 months, 6 months and 12 months after baseline)
  • Cardiovascular events and all-cause death (baseline and 24 months after baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-20
Completion: 2027-12-31
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 1200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xijing Hospital
Collaborators: The First Affiliated Hospital of Zhengzhou University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Sichuan Academy of Medical Sciences, Second Affiliated Hospital, Zhejiang University, School of Medicine, Second Affiliated Hospital of Xi'an Jiaotong University, Shaanxi Provincial People's Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Tang-Du Hospital, LanZhou University
Contact Information
Study Contact:
Qianqian Dong, Doctor
+8613720451039
dongqq@fmmu.edu.cn
Qianqian Dong, Doctor
+8613720451039
dongqq@fmmu.edu.cn
Xijing hospital
Interventions
  • Behavioral: pharmacist-led multifaceted intervention — Based on the blood pressure management model of pharmacist-led multifaceted intervention, clinical pharmacists who have received unified training provide pharmaceutical intervention and lifestyle guidance to subjects in the intervention group according to standard protocol. Pharmaceutical interventions include health education, medication adherence (medication consultation, medication reminder), medication reorganization, and rational use of medication. At the same time, clinical pharmacists supervise the subjects to change their lifestyle (including reasonable diet, quitting smoking and drinking, moderate exercise, weight control and ensuring sleep, etc.), and guide the subjects to conduct home blood pressure monitoring.
  • Behavioral: conventional health education — The subjects receive conventional hypertension health education, standard blood pressure measurement training and regular follow-up in the control group.
Study Locations (1 sites)
Xijing hospital, Xi'an, Shaanxi 710032 China
Eligibility Criteria
Inclusion Criteria (subjects must meet all of the following criteria to be included): * 1\) age 18-80 years; * 2\) patients with hypertension (diagnostic criteria: defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg according to the "Guidelines for the prevention and treatment of hypertension in China in 2023", based on the blood pressure measurement of three times on different days), who are currently taking anti-hypertensive medication and are judged by the research physician to have poor blood pressure control; * 3\) able to use smartphones and WeChat proficiently, and can communicate and upload pictures proficiently; * 4\) able to take care of yourself and communicate normally, and willing to cooperate with the research physician to complete the study and follow-up; * 5\) permanent residents of the city where the center is located; * 6\) voluntarily participate and sign the informed consent form Exclusion Criteria(subjects will be excluded if they meet any of the following criteria): * 1\) patients with advanced disease (such as patients undergoing dialysis or liver failure), or with a life expectancy of less than 2 years as determined by the research physician; * 2\) combined with psychiatric disease, cognitive impairment, communication disorder, or inability to cooperate with the researchers; * 3\) combined with cerebrovascular disease, stroke, severe liver and kidney dysfunction, severe heart failure, cancer and history of organ transplantation, etc.; * 4\) patients who are pregnant, breastfeeding, or planning to conceive in the next 2 years.
Conditions Hypertension
Phase NA
Enrollment 160
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Based on previous published research in animals and human, the investigators hypothesize that electroacupuncture (EA) will have a positive effect on hypertension.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Procedure: Electro-acupuncture control — First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.
  • Procedure: Electro-acupuncture test — First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA. At end of 8-week treatment, 24 hours blood pressure and heart rate will be measured.

Primary Outcomes

  • blood pressure (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2003-02
Completion: 2027-12
Eligibility
Age: 18 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Irvine
Principal Investigators:
  • Shaista Malik, MD, PhD, MPH (PRINCIPAL_INVESTIGATOR) - University of California, Irvine
  • Liang-Wu Fu, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of California, Irvine
  • LiFang Xie, PhD, LAc (PRINCIPAL_INVESTIGATOR) - University of California, Irvine
Contact Information
Study Contact:
Stephanie Tjen-A-Looi, PhD
9494005909
stjenalo@uci.edu
Shaista Malik, MD, PhD, MPH
smalik@uci.edu
Mitchell Beasley, MD, PhD, MPH
949-824-7000
beasleym@uci.edu
Susan Samueli Integrative Health Institute
Interventions
  • Procedure: Electro-acupuncture control — First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.
  • Procedure: Electro-acupuncture test — First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA. At end of 8-week treatment, 24 hours blood pressure and heart rate will be measured.
Study Locations (2 sites)
Susan Samueli Integrative Health Institute, Irvine, California 92617 United States
UCIMedical Center, Orange, California 92868 United States
Eligibility Criteria
Inclusion Criteria: * Patients with mild coronary disease, and no significant ECG change reflecting ischemia at rest. * Patients with high blood pressure with or without antihypertensive medication. Exclusion Criteria: * Pregnant or nursing women * Individuals with severe coronary disease (continuous angina) * Conduction abnormalities on ECG consistent with left bundle branch block * Cardiac arrhythmias associated with low blood pressure (90 mmHg) * Peripheral vascular disease * Orthopedic disease * Diabetic or psychological illness that could interfere with safe performance of exercise of psychophysiological stress testing * Those with known sensitivity to topical preparations or strong reactions to medical dressings and skin tapes